Table 1.
The results of in vitro cytotoxicity testing (expressed as mean IC50 values with standard deviations (SD) calculated out of at least three independent experiments in μM) of complexes 1–5 on the following human cancer cell lines: breast adenocarcinoma (MCF-7), osteosarcoma (HOS), lung adenocarcinoma (A549), prostate adenocarcinoma (PC-3), ovarian carcinoma (A2780), ovarian carcinoma resistant to cisplatin (A2780R), colorectal carcinoma (Caco-2), and THP-1, and toxicity against primary culture of human hepatocytes (Hep). The cytotoxicity of the complexes is compared to the free ligand HL (pomiferin) and platinum-containing chemotherapeutic drug cisplatin.
| Comp. | MCF-7 | HOS | A549 | PC-3 | A2780 | A2780R | Caco-2 | THP-1 * | Hep |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 23.8 ± 0.2 | 21.5 ± 1.4 | 20.8 ± 1.5 | 22.1 ± 1.9 | 12.1 ± 1.5 | 5.6 ± 0.3 | 13.7 ± 7.4 | 4.0 ± 1.1 | >100 |
| 2 | 29.6 ± 2.0 | 21.1 ± 1.6 | 20.9 ± 0.9 | >50 | 5.4 ± 2.4 | 5.3 ± 1.1 | 5.1 ± 1.6 | 7.9 ± 1.1 | >100 |
| 3 | 5.9 ± 0.6 | 3.5 ± 0.1 | 3.5 ± 0.2 | 13.0 ± 1.4 | 5.8 ± 2.2 | 2.9 ± 1.2 | 4.2 ± 1.9 | >10 | >100 |
| 4 | 16.0 ± 1.1 | 2.6 ± 0.5 | 8.7 ± 0.8 | 13.0 ± 1.1 | 12.8 ± 3.1 | 6.6 ± 2.3 | 22.9 ± 12.9 | 3.3 ± 1.2 | >100 |
| 5 | 3.0 ± 0.5 | 2.4 ± 0.9 | 3.1 ± 0.2 | 3.3 ± 0.1 | 2.5 ± 0.9 | 2.2 ± 0.5 | 2.6 ± 1.6 | 3.1 ± 1.1 | >100 |
| pomiferin | 22.0 ± 0.1 | 20.7 ± 0.5 | 21.2 ± 1.4 | 18.5 ± 0.7 | 8.4 ± 2.0 | 4.3 ± 1.3 | 19.8 ± 2.4 | >10 | >50 |
| cisplatin | 30.8 ± 1.8 | 30.0 ± 5.9 | >80 | >80 | 26.3 ± 2.1 | >80 | >80 | n.t. | >80 |
* incubated with the tested complexes in serum-free medium for 24 h, result calculated from six independent experiments n.t. = not tested.